Should You Buy Indaptus Therapeutics Inc (INDP) Stock After it Has Gained 0.44% in a Week?

Indaptus Therapeutics Inc (INDP) stock is up 0.44% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Indaptus Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on INDP!

See Full INDP Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With INDP Stock Today?

Indaptus Therapeutics Inc (INDP) stock is down -8.43% while the S&P 500 has gained 0.12% as of 1:56 PM on Thursday, Mar 28. INDP is down -$0.21 from the previous closing price of $2.49 on volume of 48,830 shares. Over the past year the S&P 500 is up 32.32% while INDP has gained 29.55%. INDP lost -$1.84 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Indaptus Therapeutics Inc click here.

More About Indaptus Therapeutics Inc

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. Click Here to get the full Stock Report for Indaptus Therapeutics Inc stock.